CEL-SCI Reports Second Quarter Fiscal Year 2016 Financial Results
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended March 31, 2016.
Key corporate and clinical developments during second quarter fiscal year 2016 include:
• Enrolled an additional 186 patients in the global pivotal Phase 3 head and neck cancer trial during the first six months of FY 2016, a 32% increase in enrollment compared to the first six months of FY 2015.
Key corporate and clinical developments during second quarter fiscal year 2016 include:
• Enrolled an additional 186 patients in the global pivotal Phase 3 head and neck cancer trial during the first six months of FY 2016, a 32% increase in enrollment compared to the first six months of FY 2015.